Co-Diagnostics Inc
codiagnostics.comWhat Do They Do?
Sells molecular diagnostic reagents and PCR tests to clinical laboratories, and develops a portable PCR testing system for point-of-care and at-home settings.
10-K for FY2025, filed Mar 31, 2026Co-Diagnostics, Inc., a Utah corporation (the “Company” or “CODX”), develops, manufactures and sells reagents used for diagnostic tests…View ↗
We have developed a portable diagnostic device and test system designed for point-of-care and at-home use. The system is comprised of our…View ↗
Using our proprietary test design system and reagents, we have designed and obtained regulatory clearance in the European Community and in…View ↗
How Do They Make Money?
-
10-K for FY2025, filed Mar 31, 2026
FY2025 revenue by product or service ↗
$622.5K
-
10-K for FY2025, filed Mar 31, 2026
$622.5K ↗
| Segment | Share | Revenue |
|---|---|---|
|
Product
|
67% |
Product, FY2025
$418.2K Sources
|
|
Grant
|
33% |
Grant, FY2025
$204.3K Sources
|
Who Are Their Customers?
Clinical laboratories buy diagnostic tests, with sales abroad handled through distributors; in India, CoSara jointly sells and markets tests.
10-K for FY2025, filed Mar 31, 2026Using our proprietary test design system and reagents, we have designed and obtained regulatory clearance in the European Community and in…View ↗
We believe our proprietary and patented molecular diagnostics technology is paving the way for innovation in disease detection and life…View ↗
In January 2017, the Company entered into an agreement to manufacture diagnostics tests for seven infectious diseases with a pharmaceutical…View ↗
Do Revenues Turn Into Profits?
No. It lost $46.9M in FY2025.
10-K for FY2025, filed Mar 31, 2026
−$50.2MView ↗
10-K for FY2025, filed Mar 31, 2026
−$46.9MView ↗
10-K for FY2025, filed Mar 31, 2026
−$29.8MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$6.3MView ↗
- ▼ −19% (Loss)
- vs −$7.7M in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 13, 2026
Open tableView ↗
-
Sep 4, 2026
Chief financial officer left; finance executive took over principal financial role
Brian Brown left, and Daniel Bohrer became principal financial officer and principal accounting officer.
Sources
8-K, filed Sep 4, 2026
On September 2, 2026, Co-Diagnostics, Inc. (the “Company”) and Brian Brown, the Company’s Chief Financial Officer, determined that Mr.…View ↗
Shrinking. Revenue fell 99% in 4 years, from $97.9M in FY2021 to $622.5K in FY2025, about 72% a year.
Who Do They Compete With?
Competes with BioMerieux, Siemens, Qiagen, Roche Diagnostics, Cepheid, Abbott Laboratories, Becton Dickinson, and Johnson and Johnson
10-K for FY2025, filed Mar 31, 2026The molecular diagnostics industry is extremely competitive. There are many firms that provide some or all of the products we provide and…View ↗
Loading...
